- BRCA wild-type tumors are historically difficult to treat and are associated with poorer outcomes5,6
- In the non-gBRCAmut cohort, approximately 13.4% of women were known to be sBRCAmut3
Continued platinum eligibility was achieved in 73% of non-gBRCAmut patients receiving ZEJULA and 47% of patients receiving placebo1
Platinum eligibility was defined by a platinum-free interval of ≥6 months.7
This analysis is exploratory in nature; it does not control for type 1 error and is not powered to determine treatment effect.1
Is There More That Can Be Done for BRCAwt Patients?
Learn about the effectiveness of PARP inhibitors in difficult-to-treat BRCAwt patients.
NOVA: Similar magnitude of benefit within key demographic and prognostic subgroups3
BRCA, breast cancer susceptibility gene; BRCAwt; BRCA wild type; CI, confidence interval; gBRCAmut, germline BRCA mutated; HR, hazard ratio; HRD, homologous recombination deficiency; HRDneg, HRD negative; HRDpos, HRD positive; non-gBRCAmut, not germline BRCA mutated; PFS, progression-free survival; PR, partial response; sBRCAmut, somatic BRCA mutated.
References: 1. Data on file. TESARO, Inc. 2. ZEJULA (niraparib) [package insert]. Waltham, MA: TESARO, Inc.; October 2019. 3. Mirza MR, Monk BJ, Herrstedt J, et al; ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154-2164, and Supplementary Appendix. 4. Matulonis UA, Herrstedt J, Tinker AV, et al. Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Poster presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Poster 5534. 5. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913-917. 6. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-921. 7. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer V.4.2017. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed January 16, 2018. To view the most recent and complete version of the guidelines, go online to NCCN.org.